VEA
FHTX icon

Virtus ETF Advisers’s Foghorn Therapeutics FHTX Stock Holding History

Virtus ETF Advisers’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-8,258
Closed -$71K – 459
2022
Q3 		$71K Buy
8,258
+60
+0.7% +$772 0.03% 431
2022
Q2 		$111K Buy
+8,198
New +$106K 0.04% 405

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Virtus ETF Advisers's FHTX Position: Q4 2022 in Review

Virtus ETF Advisers sold out of Foghorn Therapeutics (FHTX) in Q4 2022, closing a stake of 8,258 shares — an estimated $71K sold.

Virtus ETF Advisers first reported a position in FHTX in Q2 2022 and held it in 2 quarters. The position peaked at $111K in Q2 2022. 65 funds tracked by Wall St. Rank hold FHTX as of Q4 2022.

  • Virtus ETF Advisers reported no remaining Foghorn Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Virtus ETF Advisers sold 8,258 Foghorn Therapeutics shares in Q4 2022, an estimated $71K.
  • Virtus ETF Advisers first reported a position in Foghorn Therapeutics in Q2 2022 and held it in 2 quarters.
  • Virtus ETF Advisers's Foghorn Therapeutics position peaked at $111K in Q2 2022.
  • 65 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q4 2022.

Based on Virtus ETF Advisers's 13F filing for Q4 2022, filed 14 Feb 2023.